دورية أكاديمية
أعرض في EDS

Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.

التفاصيل البيبلوغرافية
العنوان: Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.
المؤلفون: Penack O; Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany olaf.penack@charite.de.; EBMT Transplant Complications Working Party, Heidelberg, Germany., Luft T; Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Peczynski C; EBMT Transplant Complications Working Party, Paris, France.; Department of Haematology, Sorbonne University, Paris, France., Benner A; German Cancer Research Centre, Heidelberg, Germany., Sica S; Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy., Arat M; Florence Nightingale Hospital, Hematopoietic SCT Unit, Demiroglu Bilim University Istanbul, Istanbul, Turkey., Itäla-Remes M; Turku University Hospital FI, Turku, Finland., Corral LL; Department for Haematology, Hospital Clinico San Carlos, Salamanca, Spain., Schaap NPM; Department of Hematology, Radboudumc, Nijmegen, The Netherlands., Karas M; Hospital Dept. of Hematology/Oncology, Charles University, Pilsen, Czech Republic., Raida L; Olomouc University Social Health Institute, Olomouc, Czech Republic., Schroeder T; Dept. of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Dreger P; Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Metafuni E; Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy., Ozcelik T; Florence Nightingale Hospital, Hematopoietic SCT Unit, Demiroglu Bilim University Istanbul, Istanbul, Turkey., Sandmaier BM; University of Washington, Seattle, Washington, USA., Kordelas L; Dept. of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Moiseev I; EBMT Transplant Complications Working Party, Paris, France.; First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation., Schoemans H; EBMT Transplant Complications Working Party, Paris, France.; Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium., Koenecke C; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Basak GW; EBMT Transplant Complications Working Party, Paris, France.; Department of Hematology, Oncology and Internal Medicine, the Medical University of Warsaw, Warsaw, Poland., Peric Z; EBMT Transplant Complications Working Party, Paris, France.; Department of Hematology, University of Rijeka, Rijeka, Croatia.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jan 09; Vol. 12 (1). Date of Electronic Publication: 2024 Jan 09.
نوع المنشور: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects, Adult ; Humans ; Prospective Studies ; Retrospective Studies ; Blood Platelets ; Creatinine
مستخلص: Background: We previously reported that the "Endothelial Activation and Stress Index" (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell transplantation (alloSCT) when used as continuous score. For broad clinical implementation, a prospectively validated EASIX-pre cut-off is needed that defines a high-risk cohort and is easy to use.
Method: In the current study, we first performed a retrospective cohort analysis in n=2022 alloSCT recipients and identified an optimal cut-off for predicting non-relapse mortality (NRM) as EASIX-pre=3. For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network.
Results: Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. NRM at 2 years was 31.1% in the high EASIX group versus 11.5% in the low EASIX group (p<0.001). Patients with high EASIX-pre also had worse 2 years overall survival (51.6% vs 70.9%; p=0.002). We were able to validate the cut-off and found that EASIX ≥3 was associated with more than twofold increased risk for NRM in multivariate analysis (HR=2.18, 95% CI 1.2 to 3.94; p=0.01). No statistically significant difference could be observed for the incidence of relapse.
Conclusions: The results of this study provide a prospectively validated standard laboratory biomarker index to estimate the transplant-related mortality risk after alloSCT. EASIX ≥3 taken before conditioning identifies a population of alloSCT recipients who have a more than twofold increased risk of treatment-related mortality.
Competing Interests: Competing interests: OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is a member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution. She has also received non-financial support from Gilead, the EBMT (European Society for Blood and Marrow transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research).
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Cancer. 2009 Oct 15;115(20):4715-26. (PMID: 19642176)
BMC Cancer. 2022 Jul 25;22(1):816. (PMID: 35879680)
Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5. (PMID: 16041306)
J Clin Oncol. 2014 Oct 20;32(30):3421-7. (PMID: 25225421)
Bone Marrow Transplant. 1995 Jun;15(6):825-8. (PMID: 7581076)
Blood. 2017 Apr 6;129(14):2021-2032. (PMID: 28096092)
Blood Cancer J. 2019 Nov 11;9(11):85. (PMID: 31712595)
Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33. (PMID: 12720215)
Bone Marrow Transplant. 2016 Oct;51(10):1283-1300. (PMID: 27272454)
Lancet. 1998 Oct 3;352(9134):1087-92. (PMID: 9798583)
Haematologica. 2021 Feb 01;106(2):446-453. (PMID: 31974195)
J Clin Oncol. 2018 Mar 10;36(8):789-800. (PMID: 29369699)
Blood Adv. 2021 Sep 14;5(17):3397-3406. (PMID: 34432870)
J Clin Med. 2021 Sep 24;10(19):. (PMID: 34640390)
Intensive Care Med. 2022 Jun;48(6):753-755. (PMID: 35429256)
Blood. 2012 Jul 26;120(4):905-13. (PMID: 22709687)
Haematologica. 2007 Jan;92(1):95-100. (PMID: 17229640)
BMC Cancer. 2020 Aug 24;20(1):803. (PMID: 32831058)
Blood. 2016 Feb 25;127(8):989-96. (PMID: 26603840)
J Clin Oncol. 2007 Sep 20;25(27):4246-54. (PMID: 17724349)
Front Immunol. 2022 Apr 08;13:877477. (PMID: 35464403)
Bone Marrow Transplant. 2020 Mar;55(3):553-561. (PMID: 31558788)
Front Immunol. 2021 Jun 23;12:634416. (PMID: 34248931)
Lancet Haematol. 2017 Sep;4(9):e414-e423. (PMID: 28733186)
Blood. 2011 Aug 11;118(6):1685-92. (PMID: 21636856)
فهرسة مساهمة: Keywords: Hematologic Neoplasms; Immunotherapy; Inflammation
المشرفين على المادة: AYI8EX34EU (Creatinine)
تواريخ الأحداث: Date Created: 20240110 Date Completed: 20240112 Latest Revision: 20240315
رمز التحديث: 20240315
مُعرف محوري في PubMed: PMC10806535
DOI: 10.1136/jitc-2023-007635
PMID: 38199608
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2023-007635